Medical Therapy of Constipation: Current Standards and Beyond

被引:15
作者
Andresen, Viola [1 ]
Layer, Peter [1 ]
机构
[1] Univ Hamburg, Israelit Hosp, Hamburg, Germany
关键词
Laxatives; Prucalopride; Linaclotide; PAMORA; OIC; IRRITABLE-BOWEL-SYNDROME; OPIOID-INDUCED CONSTIPATION; CHRONIC IDIOPATHIC CONSTIPATION; PLACEBO-CONTROLLED TRIAL; GUANYLATE CYCLASE-C; DOUBLE-BLIND; PHARMACOLOGICAL THERAPIES; INTEGRATED ANALYSIS; CLINICAL-TRIALS; IBS-C;
D O I
10.1159/000488695
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic constipation is a very common medical problem with relevant impact on the patients' quality of life. Modern definitions recognize constipation as a polysymptomatic disorder, including various aspects of disturbed defecation. Current guidelines recommend a stepwise approach in the management of chronic constipation. Isolated or concomitant evacuation disorders should be identified and may need differential/ additional treatment. Baseline measures include lifestyle components and bulking agents. The next step recommends treatment with conventional laxatives. In refractory patients, modern medical therapies, such as the prokinetic prucalopride or the secretagogues linalotide or lubiprostone, may be used effectively. For patients with opioid-induced constipation, the modern concept of peripherally acting mu-opioid antagonists has shown to successfully improve this increasing medical problem and even to potentially increase survival time in terminally ill patients on opioid therapy. Prolonged- released oral naloxone (in fixed combination with oxycodone), oral naloxegol or naldemedine, and subcutaneous methylnaltrexone have all demonstrated good efficacy and tolerability in the treatment of opioid-induced constipation. To adequately apply stepwise treatment algorithms, a simple tool to identify treatment failure may improve patient care. (C) 2018 S. Karger GmbH, Freiburg.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 38 条
[21]   Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].
Li, Fan ;
Fu, Tao ;
Tong, Wei-Dong ;
Liu, Bao-Hua ;
Li, Chun-Xue ;
Gao, Yu ;
Wu, Jin-Song ;
Wang, Xiang-Feng ;
Zhang, An-Ping .
MAYO CLINIC PROCEEDINGS, 2016, 91 (04) :456-468
[22]   Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study [J].
Mendzelevski, Boaz ;
Ausma, Jannie ;
Chanter, Dennis O. ;
Robinson, Patricia ;
Kerstens, Rene ;
Vandeplassche, Lieve ;
Camm, John .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) :203-209
[23]   Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints [J].
Quigley, E. M. M. ;
Tack, J. ;
Chey, W. D. ;
Rao, S. S. ;
Fortea, J. ;
Falques, M. ;
Diaz, C. ;
Shiff, S. J. ;
Currie, M. G. ;
Johnston, J. M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (01) :49-61
[24]   Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study [J].
Quigley, E. M. M. ;
Vandeplassche, L. ;
Kerstens, R. ;
Ausma, J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) :315-328
[25]   Long-term outcome of prucalopride for chronic constipation: a single-centre study [J].
Rao, P. K. Dhruva ;
Lewis, M. ;
Peiris, S. P. M. ;
Shah, P. R. ;
Haray, P. N. .
COLORECTAL DISEASE, 2015, 17 (12) :1079-1084
[26]   A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation [J].
Rao, Satish ;
Lembo, Anthony J. ;
Shiff, Steven J. ;
Lavins, Bernard J. ;
Currie, Mark G. ;
Jia, Xinwei D. ;
Shi, Kelvin ;
MacDougall, James E. ;
Shao, James Z. ;
Eng, Paul ;
Fox, Susan M. ;
Schneier, Harvey A. ;
Kurtz, Caroline B. ;
Johnston, Jeffrey M. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) :1714-1724
[27]   Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials [J].
Sajid, Muhammad S. ;
Hebbar, Madhu ;
Baig, Mirza K. ;
Li, Andy ;
Philipose, Zinu .
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2016, 22 (03) :412-422
[28]   Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis [J].
Shah, Eric D. ;
Kim, Hyungjin Myra ;
Schoenfeld, Philip .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (03) :329-338
[29]   Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation [J].
Shin, A. ;
Camilleri, M. ;
Kolar, G. ;
Erwin, P. ;
West, C. P. ;
Murad, M. H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (03) :239-253
[30]   Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes [J].
Siemens, Waldemar ;
Becker, Gerhild .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 :401-412